NovaBridge Biosciences Statistics
Total Valuation
NBP has a market cap or net worth of $204.70 million. The enterprise value is -$3.08 million.
| Market Cap | 204.70M |
| Enterprise Value | -3.08M |
Important Dates
The next estimated earnings date is Wednesday, August 19, 2026, before market open.
| Earnings Date | Aug 19, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
NBP has 115.65 million shares outstanding. The number of shares has increased by 17.96% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 115.65M |
| Shares Change (YoY) | +17.96% |
| Shares Change (QoQ) | +10.88% |
| Owned by Insiders (%) | 7.46% |
| Owned by Institutions (%) | 20.24% |
| Float | 64.21M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 0.88 |
| P/TBV Ratio | 0.89 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 8.09, with a Debt / Equity ratio of 0.01.
| Current Ratio | 8.09 |
| Quick Ratio | 7.91 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -40.89% and return on invested capital (ROIC) is -330.29%.
| Return on Equity (ROE) | -40.89% |
| Return on Assets (ROA) | -24.90% |
| Return on Invested Capital (ROIC) | -330.29% |
| Return on Capital Employed (ROCE) | -40.35% |
| Weighted Average Cost of Capital (WACC) | 12.06% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$2.94M |
| Employee Count | 30 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -16.11% in the last 52 weeks. The beta is 1.45, so NBP's price volatility has been higher than the market average.
| Beta (5Y) | 1.45 |
| 52-Week Price Change | -16.11% |
| 50-Day Moving Average | 1.76 |
| 200-Day Moving Average | 3.15 |
| Relative Strength Index (RSI) | 47.00 |
| Average Volume (20 Days) | 712,387 |
Short Selling Information
The latest short interest is 3.47 million, so 5.01% of the outstanding shares have been sold short.
| Short Interest | 3.47M |
| Short Previous Month | 4.16M |
| Short % of Shares Out | 5.01% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 5.18 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -94.27M |
| Pretax Income | -88.34M |
| Net Income | -88.34M |
| EBITDA | -94.20M |
| EBIT | -94.27M |
| Earnings Per Share (EPS) | -$0.92 |
Balance Sheet
The company has $210.84 million in cash and $3.07 million in debt, with a net cash position of $207.78 million or $1.80 per share.
| Cash & Cash Equivalents | 210.84M |
| Total Debt | 3.07M |
| Net Cash | 207.78M |
| Net Cash Per Share | $1.80 |
| Equity (Book Value) | 230.94M |
| Book Value Per Share | 2.00 |
| Working Capital | 190.63M |
Cash Flow
In the last 12 months, operating cash flow was -$20.60 million and capital expenditures -$7,000, giving a free cash flow of -$20.60 million.
| Operating Cash Flow | -20.60M |
| Capital Expenditures | -7,000 |
| Depreciation & Amortization | 68,000 |
| Net Borrowing | n/a |
| Free Cash Flow | -20.60M |
| FCF Per Share | -$0.18 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
NBP does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -17.96% |
| Shareholder Yield | -17.96% |
| Earnings Yield | -43.16% |
| FCF Yield | -10.07% |
Analyst Forecast
The average price target for NBP is $8.00, which is 351.98% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $8.00 |
| Price Target Difference | 351.98% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 4 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |